TBPH Stock Overview
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Theravance Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.62 |
| 52 Week High | US$11.83 |
| 52 Week Low | US$7.53 |
| Beta | 0.53 |
| 1 Month Change | -5.35% |
| 3 Month Change | 10.05% |
| 1 Year Change | 15.94% |
| 3 Year Change | -64.60% |
| 5 Year Change | -56.55% |
| Change since IPO | -53.75% |
Recent News & Updates
Recent updates
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why
Apr 21Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)
Mar 13Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 08Would Shareholders Who Purchased Theravance Biopharma's (NASDAQ:TBPH) Stock Year Be Happy With The Share price Today?
Feb 01Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)
Dec 09
Shareholder Returns
| TBPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.4% | -2.1% | 0.2% |
| 1Y | 15.9% | 2.8% | -13.6% |
Return vs Industry: TBPH exceeded the US Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: TBPH exceeded the US Market which returned -9.2% over the past year.
Price Volatility
| TBPH volatility | |
|---|---|
| TBPH Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TBPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: TBPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 159 | Rick Winningham | https://www.theravance.com |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease.
Theravance Biopharma, Inc. Fundamentals Summary
| TBPH fundamental statistics | |
|---|---|
| Market Cap | US$714.19m |
| Earnings (TTM) | -US$70.74m |
| Revenue (TTM) | US$51.64m |
13.8x
P/S Ratio-10.1x
P/E RatioIs TBPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBPH income statement (TTM) | |
|---|---|
| Revenue | US$51.64m |
| Cost of Revenue | US$91.40m |
| Gross Profit | -US$39.76m |
| Other Expenses | US$30.98m |
| Earnings | -US$70.74m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | -76.98% |
| Net Profit Margin | -136.98% |
| Debt/Equity Ratio | 0% |
How did TBPH perform over the long term?
See historical performance and comparison